Publications

Export 111 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Abdel Badaee, H., A. Edrees, S. Amin, M. Elamir, and G. Ragab, "Activated protein C resistance in Behcet's disease", Thrombosis Journal, vol. 11, issue 1, 2013. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Abdel Badaee, H., A. Edrees, S. Amin, M. El Amir, and G. Ragab, "Activated protein C resistance in Behcet’s disease", Thrombosis journal, vol. 11, issue 1: BioMed Central, pp. 1-5, 2013. Abstract
n/a
Abdel Badaee, H., A. Edrees, S. Amin, M. El Amir, and G. Ragab, "Activated protein C resistance in Behcet's disease.", Thrombosis journal, vol. 11, issue 1, pp. 17, 2013. Abstract

Behcet's disease is a chronic multi-system disorder of unknown etiology with protean manifestations. Venous thromboembolism is more common than arterial thrombosis, with deep vein thrombosis being the most frequent. Endothelial dysfunction resulting from vascular inflammation is considered to be an important factor of thrombosis, although the endothelial injury itself cannot completely explain the hypercoagulable state of the disease because other vasculitis syndromes do not increase the risk of thrombosis. The aim of this study is to evaluate the prevalence of activated protein C resistance (APC-R) in Egyptian patients with Behcet's disease. Also, to detect hyperhomocysteinemia in selected cases (with vascular complications) to assess their relationship with thromboembolic complications. The APC resistance ratio mean in the group of patients with vascular involvement was 2.6 ± 0.8 which was less than the group with no vascular involvement 2.8 ± 0.6, with non- significant P-value (0.5). There was more incidence of ocular lesions in the group of patients with high homocysteine level than the group of patients with normal homocytsteine level with significant P-value (0.08).

Al Saleh, J., G. Ragab, P. Nash, H. Halabi, A. Laatar, A. M. El-Sayed Yousef, H. Ehsouna, and M. Hammoudeh, "Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?", Clinical rheumatology, vol. 34, issue 1, pp. 1-8, 2015 Jan. Abstract
n/a
Al Saleh, J., G. Ragab, P. Nash, H. Halabi, A. Laatar, A. E. - S. M. Yousef, H. Ehsouna, and M. Hammoudeh, Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?, : Springer London, 2015. Abstract
n/a
Al Saleh, J., G. Ragab, P. Nash, H. Halabi, A. Laatar, A. M. El-Sayed Yousef, H. Ehsouna, and M. Hammoudeh, "Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?", Clinical Rheumatology, vol. 34, issue 1: Springer London, 2015. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Al-Nahas, Z., M. Fawzy, manal el menyawi, O. Shaker, and G. Ragab, "25-hydroxyvitamin D3 deficiency and vitamin D receptor polymorphisms in Egyptian patients with Behçet’s disease: a pilot study", International Journal of Clinical Rheumatology, vol. 12, pp. 20-27, 2017. Abstract
n/a
Alnahas, Z., manal el menyawi, M. Fawzy, O. Shaker, and G. Ragab, "173. 25-HYDROXYVITAMIN D3 DEFICIENCY AND VITAMIN D RECEPTOR POLYMORPHISMS IN EGYPTIAN BEHÇET’S DISEASE PATIENTS: A PILOT STUDY", Rheumatology, vol. 58, issue Supplement_2: Oxford University Press, pp. kez060, 2019. Abstract
n/a
B
Beshlawy, A. E., A. E. R. Zekri, M. S. Ramadan, Y. M. M. Selim, A. Abdel-Salam, M. T. Hegazy, L. Ragab, C. Gaggiano, L. Cantarini, and G. Ragab, "Genotype–phenotype associations in familial Mediterranean fever: a study of 500 Egyptian pediatric patients", Clinical Rheumatology, vol. 41, issue 5: Springer Science and Business Media Deutschland GmbH, pp. 1511 - 1521, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
C
Cacoub, P., S. N. Si ahmed, Y. ferfar, S. Pol, D. Thabut, C. Hezode, L. Alric, C. Comarmond, G. Ragab, L. Quartuccio, et al., "Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis", Clinical Gastroenterology and Hepatology, vol. 17, issue 3: W.B. Saunders, pp. 518 - 526, 2019. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Cacoub, P., S. Nafa Si Ahmed, Y. Ferfar, S. N. Pol, D. Thabut, C. Hezode, L. Albric, C. Comarmond, G. Ragab, and L. Quartuccio, "All Oral Interferon-Free Antivirals for Hepatitis C Virus Cryoglobulinemia Vasculitis: A Long Term Follow up Multicenter International Study", ARTHRITIS & RHEUMATOLOGY, vol. 69: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2017. Abstract
n/a
Cacoub, P., S. Pol, D. Thabut, C. Hezode, L. Alric, C. Comarmond, G. Ragab, L. Quatuccio, M. Hegazy, and T. Poynard, OP0235 Interferon-free antivirals for hepatitis c virus-associated cryoglobulinemia vasculitis: a long-term follow-up study, : BMJ Publishing Group Ltd, 2018. Abstract
n/a
Cacoub, P., S. Nafa Si Ahmed, Y. Ferfar, S. Pol, D. Thabut, C. Hezode, L. Alric, C. Comarmond, G. Ragab, and L. Quartuccio, "Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis", Clinical Gastroenterology and Hepatology, vol. 17, issue 3: WB Saunders, pp. 518-526, 2019. Abstract
n/a
Casa, F. D., A. Vitale, S. Guerriero, J. Sota, R. Cimaz, G. Ragab, P. Ruscitti, R. M. R. Pereira, F. Minoia, E. Del Giudice, et al., "Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis", Ophthalmology and Therapy, vol. 11, issue 2: Adis, pp. 899 - 911, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
D
De Vita, S., L. Quartuccio, M. Isola, L. Corazza, M. Ramos-Casals, S. Retamozo, G. Ragab, N. Zoheir, M. M. El Menyawi, M. Salem, et al., "RESULTS OF THE CLASSIFICATION CRITERIA FOR CRYOGLOBULINEMIC VASCULITIS VALIDATION STUDY", ANNALS OF THE RHEUMATIC DISEASES, vol. 72: BMJ PUBLISHING GROUP BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND, pp. 640–641, 2013. Abstract
n/a
De Vita, S., L. Quartuccio, M. Isola, L. Corazza, M. Ramos-Casals, S. Retamozo, G. Ragab, N. Zoheir, M. M. El Menyawi, and M. Salem, "SAT0175 Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study", Annals of the Rheumatic Diseases, vol. 72, issue Suppl 3: BMJ Publishing Group Ltd, pp. A640-A641, 2013. Abstract
n/a
Della Casa, F., A. Vitale, R. M. Pereira, S. Guerriero, G. Ragab, G. Lopalco, M. Cattalini, I. Mattioli, P. Parronchi, M. P. Paroli, et al., "Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis", Ophthalmology and Therapy, vol. 11, issue 2: Adis, pp. 887 - 897, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Della Casa, F., A. Vitale, G. Lopalco, P. Ruscitti, F. Ciccia, G. Emmi, M. Cattalini, E. Wiesik-Szewczyk, M. C. Maggio, B. Ogunjimi, et al., "Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases", Frontiers in Medicine, vol. 9: Frontiers Media S.A., 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
DeVore, A. E., J. L. Jorizzo, N. Vigneswaran, B. K. Rodu, S. Onal, S. C. Foster, S. K. Frankel, M. I. Schwarz, S. J. Oh, and G. Ragab, "Clinical manifestations common to vasculitis", Vasculitis: Oxford University Press, pp. 115, 2007. Abstract
n/a
DeVore, A. E., J. L. Jorizzo, N. Vigneswaran, B. K. Rodu, S. Onal, S. C. Foster, S. K. Frankel, M. I. Schwarz, S. J. Oh, G. Ragab, et al., "Clinical manifestations common to vasculitis", Vasculitis: Oxford University Press, pp. 115, 2007. Abstract
n/a
E
El-Fishawy, H., G. Saadi, M. Hassaballa, M. Hussein, W. Doss, G. Ragab, and R. Barsoum, "Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective", Journal of Advanced Research, vol. 7, issue 3: Elsevier, pp. 391 - 402, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
El-Fishawy, H., G. Saadi, M. Hassaballa, M. Hussein, W. Doss, G. Ragab, and R. Barsoum, "Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective.", Journal of advanced research, vol. 7, issue 3, pp. 391-402, 2016 May. Abstract

Egypt, the single country with highest incidence of HCV infection in the world, has embarked on a government-sponsored mass treatment program using several combinations of DAAs. Recognizing the importance of extrahepatic manifestations, independently of the hepatic, a subcommittee was assigned to develop national guidelines for respective prioritizing indications and protocols. It evaluated the benefit of treating patients with different extrahepatic manifestations, and reviewed relevant clinical trials and guidelines concerning DAA combinations available in Egypt. The latter included Sofosbuvir plus either peg-interferon, Simeprevir, Ledipasvir or daclatasvir, and the Viekera family comprising paritaprevir/ritonavir + ombitasvir with (GT-1) or without (GT-4) Dasabuvir. Any of these protocols may be used with or without Ribavirin according to indication. A blueprint was subjected to peer debate in dedicated workshops in two national meetings and subsequently to an online professional review, eventually leading to a final report that was adopted by the health authorities. Seven compelling and 10 optional indications were identified for treating patients with predominantly extrahepatic manifestations. The former include kidney disease at different stages, cryoglobulinemic vasculitis and non-Hodgkin lymphoma. Selected treatment protocols, were encoded and their use was prioritized on the basis of evidence of efficacy and safety. We concluded that any of the studied protocols may be used, preferably with ribavirin, for 12-week treatment in all patients with extrahepatic manifestations without cirrhosis and with eGFR above 30 ml/min/1.73 sqm. Ribavirin should be included in protocols for treating patients with compensated cirrhosis. Daclatasvir-based protocols are recommended for decompensated cirrhosis, while the Viekera family is recommended in patients with eGFR < 30 ml/min/1.73 sqm, including those on dialysis. In kidney-transplanted patents, caution is due to avoidance of the pharmacokinetic interaction with the Cytochrome-P450 enzyme system, in-between immunosuppressive agents and most DAAs, particularly the Viekera family.

El-Fishawy, H., G. Saadi, M. Hassaballa, M. Hussein, W. Doss, G. Ragab, and R. Barsoum, "Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations–An Egyptian perspective", Journal of advanced research, vol. 7, issue 3: Elsevier, pp. 391-402, 2016. Abstract
n/a
El-Gendy, H., R. M. El-Gohary, S. Mahfouz, H. M. A. Ahmed, D. M. El Demerdash, and G. Ragab, "Multifocal avascular necrosis in a patient with refractory immune thrombocytopenia and antiphospholipid antibodies; case report and review of literature.", Platelets, pp. 1-8, 2018 Oct 29. Abstract

Avascular necrosis (AVN) is a devastating condition that is rarely reported in patients with immune thrombocytopenia (ITP). Treatment with steroids remains a major risk factor for developing AVN. However, the incidence of AVN in patients with ITP requiring corticosteroid therapy is much less than that observed with other clinical conditions requiring corticosteroids. ITP is a bleeding disorder but can be also be a pro-thrombotic state via different mechanisms and thus could result in AVN. Among the possible causes of this pro-thrombotic state is the presence of antiphospholipid antibodies (aPLs). In this case, we report a patient with refractory ITP who developed multifocal AVN around the time she acquired new aPLs. We also discuss different mechanisms by which risk of thrombosis is increased in ITP and the relationship between ITP, aPLs and antiphospholipid syndrome.

El-Gendy, H., R. M. El-Gohary, K. S. Shohdy, and G. Ragab, "Leprosy masquerading as systemic rheumatic diseases", JCR: Journal of Clinical Rheumatology, vol. 22, issue 5: LWW, pp. 264-271, 2016. Abstract
n/a
El-Gendy, H., R. M. El-Gohary, K. S. Shohdy, and G. Ragab, "Leprosy Masquerading as Systemic Rheumatic Diseases", Journal of Clinical Rheumatology, vol. 22, issue 5: Lippincott Williams and Wilkins, pp. 264 - 271, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
El-Gendy, H., R. M. El-Gohary, S. Mahfouz, H. M. A. Ahmed, D. M. El Demerdash, and G. Ragab, "Multifocal avascular necrosis in a patient with refractory immune thrombocytopenia and antiphospholipid antibodies; case report and review of literature", Platelets, vol. 30, issue 5: Taylor and Francis Ltd, pp. 664 - 671, 2019. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
El-Gendy, H., R. M. El-Gohary, K. S. Shohdy, and G. Ragab, "Leprosy Masquerading as Systemic Rheumatic Diseases.", Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, vol. 22, issue 5, pp. 264-71, 2016 Aug. Abstract

Rheumatologic manifestations not only are encountered in leprosy but also can be the first and even the sole presenting manifestation. The hallmark of leprosy is skin and peripheral nerve affection; however, it can affect a wide range of other organs, with the joints being the commonest. We have searched PubMed with the key words leprosy, arthritis, vasculitis, rheumatic diseases, and autoantibodies in a proper combination. Relevant studies were retrieved from scanning of their abstracts. The relevant references provided in these articles were also selected and reviewed. We summarize the clinical and laboratory manifestations that make leprosy masquerade as a systemic rheumatic disease. Moreover, we report 4 Egyptian patients who presented with rheumatologic manifestations, namely, arthritis and vasculitis that turned out to be leprosy related.

El-Gendy, H., R. M. El-Gohary, S. Mahfouz, H. M. A. Ahmed, D. M. El Demerdash, and G. Ragab, "Multifocal avascular necrosis in a patient with refractory immune thrombocytopenia and antiphospholipid antibodies; case report and review of literature", Platelets, vol. 30, issue 5: Taylor & Francis, pp. 664-671, 2019. Abstract
n/a
Elbendary, A., M. R. E. Abdel-Halim, and G. Ragab, "Updates in cutaneous manifestations of systemic vasculitis", Current opinion in rheumatology, vol. 34, issue 1: NLM (Medline), pp. 25 - 32, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
F
Fawzy, M., A. Edrees, H. Okasha, A. El Ashmaui, and G. Ragab, "Gastrointestinal manifestations in systemic lupus erythematosus", Lupus, vol. 25, issue 13: SAGE Publications Ltd, pp. 1456 - 1462, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Fawzy, M., A. Edrees, H. Okasha, A. El Ashmaui, and G. Ragab, "Gastrointestinal manifestations in systemic lupus erythematosus.", Lupus, 2016 Apr 6. Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by multisystem involvement, including the gastrointestinal (GI) tract. There is a significant variation in the clinical presentation and severity of GI disorders. When GI symptoms present as the initial manifestation of SLE, there is likely to be a delay in the diagnosis. The cause of these GI manifestations in SLE may be the disease, or the side effects of medications, or infections. In this study we investigated the GI manifestations in a group of SLE patients. Our study was conducted on 40 SLE patients and 30 healthy controls to assess the prevalence of GI symptoms in SLE patients. The prevalence of gastrointestinal manifestations in our study was 42.5%. GI manifestations in our SLE patients were: acute abdominal pain (due to pleurisy and peritonitis), 6%; diffuse abdominal pain, 23.5%; epigastric pain, 29%; epigastric pain with vomiting, 23.5%; epigastric pain with chronic constipation, 6%; chronic constipation, 6%; and diffuse abdominal pain with bleeding per rectum, 6%. In our study, we found a higher incidence ofGiardiainfestation in SLE patients than in healthy controls, and 10% of these patients were asymptomatic. There was moreGiardiainfestation in patients with GI symptoms as compared with patients with no GI symptoms, with aPvalue of 0.009. In our study SLE patients with GI symptoms had a peak systolic velocity (cm/s) with a mean of 108.4 ± 32.1 standard deviation (SD) in the celiac Doppler study. Patients without GI symptoms had a peak systolic velocity with a mean of 111.9 ± 37.7 SD, meaning that our patients mostly had no evidence of celiac trunk stenosis, but there was significant difference between SLE patients without GI symptoms and controls, as the mean was higher in SLE patients than in the controls. Also, the celiac end diastolic velocity was higher in both groups of SLE patients with GI symptoms and those without GI symptoms, compared to controls.

Fayed, A., M. T. Hegazy, L. Biard, M. Vieira, T. El Shabony, D. Saadoun, M. Casato, M. Visentini, G. Ragab, and P. Cacoub, "Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis after Sustained Viral Response after Interferon-Free Direct-Acting Antivirals", American Journal of Gastroenterology, vol. 117, issue 4: Wolters Kluwer Health, pp. 627 - 636, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Ferri, C., M. Ramos-Casals, A. L. Zignego, L. Arcaini, D. Roccatello, A. Antonelli, D. Saadoun, A. C. Desbois, M. Sebastiani, and M. Casato, "International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement", Autoimmunity Reviews, vol. 15, issue 12: Elsevier, pp. 1145-1160, 2016. Abstract
n/a
G
Gaggiano, C., D. Rigante, J. Hernández-Rodríguez, A. Vitale, M. Tarsia, A. Soriano, G. Lopalco, F. Iannone, M. Abdel Jaber, R. Giacomelli, et al., "Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network", Therapeutic Advances in Musculoskeletal Disease, vol. 13: SAGE Publications Ltd, 2021. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Goubran, H., J. Seghatchian, J. Radosevic, G. Ragab, and T. Burnouf, "The microbiome and transfusion in cancer patients", Transfusion and Apheresis Science, vol. 56, issue 3: Elsevier Ltd, pp. 330 - 335, 2017. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Goubran, H., G. Ragab, and S. Hassouna, Precision Anticoagulation Medicine: A Practical Guide, : Springer Nature, 2019. Abstract
n/a
Goubran, H., J. Stakiw, J. Seghatchian, G. Ragab, and T. Burnouf, "SARS-CoV-2 and cancer: The intriguing and informative cross-talk", Transfusion and Apheresis Science: Elsevier Ltd, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Goubran, H., G. Ragab, and W. Sabry, "Metabolism-mediated thrombotic microangiopathy and B12", Vitamins and Hormones, vol. 119: Academic Press Inc., pp. 441 - 455, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a